Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply

dc.contributor.advisor
dc.contributor.author	Cipriani, Andrea
dc.date.accessioned	2018-10-31T11:48:58Z
dc.date.available	2018-10-31T11:48:58Z
dc.date.issued	2018
dc.identifier.citation	Cipriani, Andrea; Adamo, Nicoletta; Del Giovani, Cinzia; Goghill, David; Banaschewski, Tobias; Hollis, Chris; Zuddas, Alessandro; Simonoff, Emily; Cortese, Samuele. Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply. Lancet Psychiatry Correspondence 2018 5(11)P871-873	en
dc.identifier.uri	https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/129
dc.description	Published online at: DOI: 10.1016/S2215-0366(18)30396-1 This is an Open Access article under the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). Copyright © 2018 Elsevier Ltd. All rights reserved.	en
dc.description.abstract	Standardised mean differences can be difficult to translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between the mean value in two groups and then estimates the average amount that the experimental intervention changes in the outcome compared with that of the control intervention.	en
dc.description.sponsorship	Supported by the NIHR
dc.language.iso	en	en
dc.subject	Risk Assessment	en
dc.subject	Attention Deficit Hyperactivity Disorder (ADHD)	en
dc.title	Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply	en
dc.type	Article	en